# Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

> **NCT03552263** · PHASE2 · COMPLETED · sponsor: **Tasly Pharmaceuticals, Inc.** · enrollment: 132 (actual)

## Conditions studied

- Acute Mountain Sickness (AMS)

## Interventions

- **DRUG:** T89 capsule
- **DRUG:** Placebo capsule

## Key facts

- **NCT ID:** NCT03552263
- **Lead sponsor:** Tasly Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-07
- **Primary completion:** 2019-10-20
- **Final completion:** 2019-11-10
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2019-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03552263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03552263, "Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03552263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*